Laboratorios Clausen S.A. would like to inform the healthcare professionals that we have reached an agreement with our product Kimatinib (Imatinib Mesylate), at the Special Techniques Laboratory of the "Asociación Española Primera de Socorros Mutuos in Montevideo- Uruguay"
Laboratorios Clausen S.A announces the launching of Interferón beta-1a Clausen in prefilled syringes 6 and 12 MIU, indicated for the treatment of relapsing-remitting Multiple Sclerosis.
